NAACCR Item #3938: ALK Rearrangement
|Item #||Length||Source of Standard||Year Implemented||Version Implemented||Year Retired||Version Retired|
NAACCR XML: Tumor.alkRearrangement
Testing for ALK rearrangement is performed for patients with advanced non-small cell lung cancer (NSCLC) to identify tumors which are sensitive to small-molecule ALK kinase inhibitors.
ALK rearrangement is recommended by treatment guidelines for patients with advanced lung cancer as a prognostic marker and factor in determining appropriate therapy. It is a new data item for cases diagnosed 01/01/2021+.
|0||Normal ALK negative Negative for rearrangement, no rearrangement identified, no mutations (somatic) identified, not present, not detected|
|1||Abnormal Rearrangement identified/detected: EML4-ALK, KIF5B-ALK, TFG-ALK, and/or KLC1-ALK|
|2||Rearrangement identified/detected: Other ALK Rearrangement not listed in code 1|
|7||Test ordered, results not in chart|
|8||Not applicable: Information not collected for this case If this information is required by your standard setter, use of code 8 may result in an edit error.|
|9||Not documented in medical record ALK Rearrangement not assessed or unknown if assessed|
|Blank||Diagnosis year is prior to 2021|
Each Site-Specific Data Item (SSDI) applies only to selected primary sites, histologies, and years of diagnosis. Depending on applicability and standard-setter requirements, SSDIs may be left blank.